Data on Mercks Pembrolizu?mab from Largest Study to Date of Investigat?ional Anti-PD-1 Antibody in Advanced Melanoma Highlighte?d at ASCO 2014
![](/46/pdcnewsitem/03/33/94/kD0n8pxsvsU6oDx.png)
MSD (Merck Sharp & Dohme Ltd) today announced new data from the company’s large ongoing Phase Ib study (KEYNOTE-001) evaluating pembrolizumab (MK-3475), Merck’s investigational anti-PD-1 antibody, as a single agent (monotherapy) in 411 patients with advanced melanoma.
Following treatment with pembrolizumab, the estimated overall survival (OS) rate at one year was 69% across all patients studied, including 74% in patients without prior ipilimumab therapy (current standard therapy) and 65% in patients who had progressive disease on or following ipilimumab. At 18 months, the estimated OS was 62%. The median OS has not been reached, with some patients receiving treatment with pembrolizumab as monotherapy for more than 2 years.[1]
These new data will be presented today in an oral session by Dr Antoni Ribas, professor, Hematology/Oncology and Surgery, and director of the Tumor Immunology Program at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO 2014) in Chicago (Abstract #LBA9000).
“Pembrolizumab looks like it has potential to be a paradigm shift for cancer therapy and is firmly helping to establish immunotherapy as one of the most exciting and promising treatment modalities in recent years,” said Dr David Chao, Consultant Medical Oncologist, Royal Free Hampstead NHS Trust. “The survival results seen in KEYNOTE-001, which are the most meaningful measures of success to doctors and patients alike, are very promising and could benefit the many patients with advanced melanoma in the UK.”
Reference
[1] Ribas A, Hodi FS, Kefford R, et al. Efficacy and Safety of the Anti-PD-1 Monoclonal Antibody MK-3475 in 411 Patients With Melanoma. Abstract #LBA9000 presented at the 2014 ASCO annual meeting.
Related News
-
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News CPHI North America 2024 – From the Floor
Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024. -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News A Day in the Life of a President and Chief Scientific Officer
We are continuing to get to know the people working day-to-day behind the pharma companies shaping the industry, the ones who keep the wheels turning and ultimately bring better healthcare to the population; we are talking to the individuals at the hea... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News LEAP-ing into the future of pharma – the CPHI Middle East Vision
On March 6, 2024, the CPHI team hosted the Future of Pharma Forum at LEAP 2024, Saudi Arabia’s premier destination for tech leaders and innovators to meet and collaborate. -
News Informa Markets International Women’s Day Panel Discussion
On March 7, 2024, the Informa Markets Amsterdam office hosted an International Women’s Day Breakfast and Panel Discussion to celebrate the women who drive the B2B events industry forward, including members of the CPHI team. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance